Cancer Risk Reduction Cancer remains the second leading cause of death in the United States, according to the CDC
In reality, however, the incorporation of lifestyle modification strategies to support patients prescribed GLP-1 medications is limited
Semaglutide is a GLP-1 medication approved by the US Food and Drug Administration (FDA) that controls blood sugar levels in people with type 2 diabetes, reduces the risk of heart attack and stroke in people with heart disease and type 2 diabetes or obesity, and promotes weight loss in people with overweight and obesity
Most published data involve earlier-generation GLP-1 agonists such as liraglutide, with emerging case series and small studies examining semaglutide and tirzepatide in post-bariatric patients
Inhibiting an endogenous metabolic enzyme can create effects beyond the intended experimental target, particularly when human exposure and long-term safety have not been established
If a provider tells you a for-sure timeline, you need to be cautious because the actual results vary from person to person based on the injury, overall rehabilitation plan, and individual healing response